Ross Thomas M. 4
4 · MAXCYTE, INC. · Filed Jul 10, 2024
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Ross Thomas M.
EVP, Global Sales
Transactions
- Sale
Common Stock
2024-07-08$4.03/sh−19,802$79,782→ 25,000 total - Exercise/Conversion
Common Stock
2024-07-08$1.64/sh+19,802$32,495→ 44,802 total - Exercise/Conversion
Common Stock
2024-07-09$1.64/sh+13,531$22,204→ 38,531 total - Sale
Common Stock
2024-07-09$4.03/sh−13,531$54,584→ 25,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-07-08−19,802→ 46,865 totalExercise: $1.64Exp: 2030-01-20→ Common Stock (19,802 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-07-09−13,531→ 33,334 totalExercise: $1.64Exp: 2030-01-20→ Common Stock (13,531 underlying)
Footnotes (4)
- [F1]The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.105, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option has fully vested.